{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=UX007",
    "query": {
      "intervention": "UX007"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T04:24:57.028Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04632953",
      "title": "Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 150,
      "start_date": "2021-11-30",
      "completion_date": "2035-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632953"
    },
    {
      "nct_id": "NCT02599961",
      "title": "Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glucose Transporter Type 1 Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 15,
      "start_date": "2015-09-10",
      "completion_date": "2019-10-22",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02599961"
    },
    {
      "nct_id": "NCT01993186",
      "title": "Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Year to 100 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-02-28",
      "completion_date": "2017-09-20",
      "has_results": true,
      "last_update_posted_date": "2020-06-19",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 8,
      "location_summary": "Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993186"
    },
    {
      "nct_id": "NCT02214160",
      "title": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency",
        "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
        "Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
        "Trifunctional Protein (TFP) Deficiency",
        "Carnitine-acylcarnitine Translocase (CACT) Deficiency"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 94,
      "start_date": "2014-12-09",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214160"
    },
    {
      "nct_id": "NCT02696044",
      "title": "Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rett Syndrome"
      ],
      "interventions": [
        {
          "name": "triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center for Rare Neurological Diseases, Norcross, GA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "2 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2016-06",
      "completion_date": "2022-02",
      "has_results": false,
      "last_update_posted_date": "2020-07-17",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 1,
      "location_summary": "Norcross, Georgia",
      "locations": [
        {
          "city": "Norcross",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02696044"
    },
    {
      "nct_id": "NCT01886378",
      "title": "A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
        "Carnitine Palmitoyltransferase (CPT II) Deficiency",
        "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency",
        "Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency",
        "Trifunctional Protein (TFP) Deficiency"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-02-06",
      "completion_date": "2016-08-25",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01886378"
    },
    {
      "nct_id": "NCT02968953",
      "title": "Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Glucose Transporter 1 Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jerry Vockley, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "3 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-02-08",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02968953"
    },
    {
      "nct_id": "NCT03665636",
      "title": "Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glycogen Storage Disease Type I"
      ],
      "interventions": [
        {
          "name": "Triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Areeg El-Gharbawy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-10-16",
      "completion_date": "2021-10-21",
      "has_results": false,
      "last_update_posted_date": "2021-12-15",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03665636"
    },
    {
      "nct_id": "NCT02960217",
      "title": "Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)"
      ],
      "interventions": [
        {
          "name": "UX007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2017-04-19",
      "completion_date": "2019-10-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Miami, Florida • Norcross, Georgia + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Norcross",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02960217"
    },
    {
      "nct_id": "NCT02500082",
      "title": "Triheptanoin (UX007) to Treat Citrate Transporter Deficiency",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Citrate Transporter Deficiency",
        "SLC13A5 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "triheptanoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Irina A Anselm",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "9 Years",
        "sex": "ALL",
        "summary": "4 Years to 9 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-01-28",
      "last_synced_at": "2026-09-06T04:24:57.028Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500082"
    }
  ]
}